HC Wainwright resumed coverage on Strongbridge Biopharma with a new price target
$SBBP
Major Pharmaceuticals
Health Care
HC Wainwright resumed coverage of Strongbridge Biopharma with a rating of Buy and set a new price target of $10.00
Save time and jump to the most important pieces.
Xeris Pharmaceuticals, Inc. and Strongbridge Biopharma plc are now subsidiaries of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Xeris Pharmaceuticals, Inc. ("Xeris"), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that it has successfully completed the previously announced acquisition of Strongbridge Biopharma plc (NASDAQ:SBBP) ("Strongbridge"). Under the terms of the acquisition agreement, the businesses of Xeris and Strongbridge are now combined under Xeris Biopharma Holdings, Inc. ("Xeris Biopharma Holdings"). Strongbridge shares and Xeris shares ceased trading on the
DUBLIN, Ireland and TREVOSE, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) (the "Company" or "Strongbridge") today announced that the High Court of Ireland (the "Court") has approved the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) ("Xeris") by means of a scheme of arrangement (the "Scheme") under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the "Act"). The Court sanction hearing in relation to the Scheme was held earlier today at which the Court sanctioned the Scheme and confirmed the related reduction of capital. The Scheme became effective earlier today on October 5, 2021 upon the r
DUBLIN, Ireland and TREVOSE, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) (the "Company" or "Strongbridge") today announced that the High Court of Ireland (the "Court") has set the date of the final court hearing to sanction the proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. ("Xeris") by means of scheme of arrangement (the "Scheme") under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the "Act"). The court hearing to sanction the Scheme is scheduled to be heard in the Commercial List of the Court sitting at the Four Courts, Inns Quay, Dublin 7, Ireland at 11:00 a.m. (Irish time) on October 5, 2021, and the Scheme is expected t
ALACHUA, Fla. and TAMPA, Fla., July 19, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that John H. Johnson has been appointed to its Board of Directors, effective July 19, 2021. Johnson will serve on both the Governance, Nominating and Sustainability Committee and the Science and Technology Committee. Johnson is a recognized leader in the biopharmaceutical industry with more than 30 years of experience in senior leadership positions, including at Johnson & Johnson, Eli Lilly & Company, ImClone, and Centocor Ortho Biotech. "John is an excellent
15-12B - Strongbridge Biopharma plc (0001634432) (Filer)
EFFECT - Strongbridge Biopharma plc (0001634432) (Filer)
EFFECT - Strongbridge Biopharma plc (0001634432) (Filer)
Craig-Hallum downgraded Strongbridge Biopharma from Buy to Hold and set a new price target of $3.25 from $9.00 previously
Craig Hallum downgraded Strongbridge Biopharma from Buy to Hold
JMP Securities downgraded Strongbridge Biopharma from Outperform to Market Perform
SC 13D/A - Strongbridge Biopharma plc (0001634432) (Subject)
SC 13D/A - Strongbridge Biopharma plc (0001634432) (Subject)
SC 13G - Strongbridge Biopharma plc (0001634432) (Subject)
4 - Strongbridge Biopharma plc (0001634432) (Issuer)
4 - Strongbridge Biopharma plc (0001634432) (Issuer)
4 - Strongbridge Biopharma plc (0001634432) (Issuer)